Skip to main content

Experimental and Developmental Therapeutics Program

The overall objective of the Experimental and Developmental Therapeutics Program is to discover, develop and test new and existing drugs. Our efforts give patients access to innovative care options close to home.

Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is a leading cancer center in Central and South Texas. Our efforts are making care more precise and minimizing side effects that may compromise patients’ quality of life.

Drugs (therapeutics) that destroy cancer cells can also damage healthy cells, leaving you with side effects. We are looking to change this by discovering and testing new targeted therapeutics in our labs.

About our Experimental and Developmental Therapeutics (EDT) Program

Our team includes experts in all aspects of cancer drug development, including clinical trials. Specialists in drug discovery, structural biology, medicinal chemistry, immunology and health data (informatics) work together. Having so many specialties in one program accelerates our ability to create and test new therapeutics. Meet our team.

EDT is one of the many ways we are advancing care as the only National Cancer Institute (NCI)-designated cancer center in Central and South Texas. We are also investigating cancer risks that are unique to our community and finding ways to help manage them. Find out more about our other cancer research programs.

How our EDT Program is advancing cancer care

We are making therapeutics more effective while reducing side effects that may make you feel sick or tired.

Our efforts include:

  • Basic science: We conduct lab studies to identify and test substances that interact with specific elements within cancer cells (therapeutic targets). We are also studying cell changes (biomarkers). These changes can tell us whether new drug therapies are benefiting patients.
  • Drug development: Our researchers combine basic science findings with health data to develop new cancer drugs. In some cases, these drugs are available to eligible patients at Mays Cancer Center up to 15 years before they are on the open market. Find out more about our Institute for Drug Development.
  • Other research: We are exploring new approaches for using existing drugs. These efforts include determining whether drugs approved for other diseases or one type of cancer may be effective in treating a different cancer.
  • Clinical trials: After new therapeutics have undergone many rounds of lab testing, we bring them to eligible patients through clinical trials. As a trusted research center, we offer years of experience and carefully follow all trial requirements to help keep eligible patients informed and safe. View a list of our cancer clinical trials.

Focus areas and care innovations

Our work is changing the way doctors care for patients across the many types of cancer we treat.

We have achieved notable findings in:

  • Brain tumor and cancer care: We are developing a novel therapy to protect healthy brain tissue in people with glioblastoma, a fast-growing cancer. This therapeutic makes it possible to deliver targeted radiation to the tumor while preventing damage to nearby healthy cells. Find out more about our brain tumor program.
  • Breast cancer therapy: Our researchers completed early studies demonstrating how an FDA-approved antidepressant inhibits the growth and spread of certain breast cancers. We are now analyzing compounds within the antidepressant to determine if it might be effective as a prevention strategy. We are also exploring how to reduce the dose of chemotherapy drugs for cancer patients without affecting outcomes. Find out more about our breast cancer program.
  • Immunotherapy: We are uncovering new knowledge about how our immune systems respond to cancer. This information is accelerating the development of immunotherapy drugs for specific types of cancer. Get more information about immunotherapy.